AZ, BMS, Lilly, Pfizer make investor's cut

Investor Osman Gulseven finds that of hundreds of healthcare companies listed on the New York Stock Exchange, only four fit his investment objective of  high profitability, substantial dividends and a maximum P/E ratio of 20. Each is a  large-cap drugmaker: AstraZeneca , Bristol-Myers Squibb, Eli Lilly & Co, and Pfizer. Article

Suggested Articles

Novavax sign
Manufacturing

Novavax enlists AGC Biologics to produce adjuvant for COVID shot

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

by Eric Sagonowsky
FDA Lab
Manufacturing

COVID-19 chaos drives need for foreign drug tests: Valisure CEO

The FDA recently asked five drug manufacturers to recall the commonly used diabetes med metformin. With COVID-19 raging, is metformin just the start?

by Kyle Blankenship
Pills Getty
Manufacturing

FDA reports shortages for antidepressant Zoloft amid pandemic

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

by Eric Sagonowsky